1. catalystcrusin
2. blueauger497
3. 48ncrebs
4. 2017rogerthat
1.48ncrebs 10/07/2017
Downgrade in future?
2.2017rogerthat 07/25/2018
Sees FY18 revs of $2.9-3.0 bln vs. $2.79 bln
3.blueauger497 02/01/2018
needs news - Barclays
4.48ncrebs 06/18/2018
Announces that IRKAMBI to treat the underlying cause of cystic fibrosis (CF)
5.catalystcrusin 01/31/2018
Maxim Group reiterates Buy rating, $195 PT
6.catalystcrusin 02/12/2018
NEWS sounds good - Announces FDA approval of FDA SYMDEKO
7.catalystcrusin 10/07/2017
Dont really care what they say, for the more part they only care about themselves.
8.catalystcrusin 02/05/2018
Beats EPS estimates by $0.07 and beats on revenues
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW